Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.90
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (BLUE)
- Company bluebird bio, Inc.
- Price $0.45
- Changes Percentage (-2.2%)
- Change -$0.01
- Day Low $0.45
- Day High $0.47
- Year High $5.53
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/25/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.50
- High Stock Price Target $25.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.63
- Trailing P/E Ratio -1.44
- Forward P/E Ratio -1.44
- P/E Growth -1.44
- Net Income $-211,913,000
Income Statement
Quarterly
Annual
Latest News of BLUE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Blue Jackets confront structure and work ethic issues after rough weekend
After tough losses to the Jets and Capitals, the Columbus Blue Jackets are facing questions about their performance. Coach Evason is pushing for improvement, emphasizing the need for better effort and...
By The New York Times | 15 hours ago -
Blue Jays free agent fits: Which hitters can help Toronto's stalling offence?
The Toronto Blue Jays are looking to boost their offense this offseason, particularly in adding power hitters. Potential free-agent targets range from superstars like Soto to complementary additions l...
By The New York Times | 15 hours ago -
Republican Larry Hogan predicts "biggest surprise upset in America" in deep blue Maryland Senate race
Maryland's U.S. Senate race is highly competitive, with Republican Larry Hogan trailing in polls but feeling underestimated. Hogan aims to attract Democratic voters and emphasizes his independent lead...
By CBS News | 1 day ago
